Figure 4. HAND2-AS1 inhibited miR-106a-5p expression. (A) miRanda database predicted data between HAND2-AS1 and miR-106a-5p. (B) Luciferase assay for WT and mutant HAND2-AS1 activity in HEK293 cells transfected with miR-NC or miR-106a-5p. n = 6, *p<0.05. (C) qRT-PCR analyzed the expression of miR-106a-5p in BT549 cells transfected with HAND2-AS1 or si-HAND2-AS1. n = 6, *p<0.05. (D) RNA-immunoprecipitation experiments were performed using miR-NC or miR-106a-5p to immunoprecipitate HAND2-AS1 in BT549 cells. (E, F) qRT-PCR analyzed HAND2-AS1 expression in TNBC tissues and cells. n = 6, *p<0.05. (G) The expression of HAND2-AS1 in TNBC tissues from patients with tumor grade 0 to grade IV (n = 6) was measured by qRT-PCR (*p<0.05 vs grade 0). The above measurement data were expressed as mean ± standard deviation. Data among multiple groups were analyzed by one-way ANOVA, followed by a Tukey post hoc test. The experiment was repeated in triplicate.